Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer: meta-analysis.

Stavroula L Kastora, Yazan A Masannat, Mairi Fuller, Ashrafun Nessa, Shafaque Shaikh

Journal: The British journal of surgery 2024;111(1):

PMID: 37890072

Abstract

BACKGROUND

Breast cancer is the most common cancer worldwide, with remarkable advances in early diagnosis, systemic treatments, and surgical techniques. Robotic nipple-sparing mastectomy has been trialled; however, the complication rates, surgical outcomes, and oncological safety of this approach remain obscure.

METHODS

A systematic search of the literature was conducted from conception until September 2022. Studies examining complications and operative variables where robotic nipple-sparing mastectomy was compared with conventional nipple-sparing mastectomy were included. Primary study outcomes were complications (Clavien-Dindo grade III complications, skin or nipple necrosis, seroma, haematoma, infection, implant loss, and wound dehiscence) and oncological safety (recurrence and positive margins). The secondary outcomes included operative variables, length of stay, cost-effectiveness, learning curve, and aesthetic outcome.

RESULTS

A total of seven studies of overall fair quality, involving 1674 patients, were included in the systematic review and meta-analysis. Grade 3 complications were reduced in robotic nipple-sparing mastectomy without statistical significance (OR 0.60 (95 per cent c.i. 0.35 to 1.05)). Nipple necrosis was significantly reduced in robotic nipple-sparing mastectomy (OR 0.54 (95 per cent c.i. 0.30 to 0.96); P = 0.03; I2 = 15 per cent). Operating time (mean difference +58.81 min (95 per cent c.i. +28.19 to +89.44 min); P = 0.0002) and length of stay (mean difference +1.23 days (95 per cent c.i. +0.64 to +1.81 days); P < 0.0001) were significantly increased in robotic nipple-sparing mastectomy, whereas the opposite was true for blood loss (mean difference -53.18 ml (95 per cent c.i. -71.78 to -34.58 ml); P < 0.0001).

CONCLUSION

Whilst still in its infancy, robotic breast surgery may become a viable option in breast surgery. Nonetheless, the oncological safety of this approach requires robust assessment.

© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.

Address: School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.; General Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.; Breast Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.; General Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.; Breast Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.; Breast Surgery, Aberdeen Royal Infirmary, Aberdeen, UK.; UCL EGA Institute for Women's Health, University College London, London, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.